SCHEMBL6368689

SCHEMBL6368689

COC(=O)CC(=O)CC(O)(CCc1cccs1)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.38
BRD4 O60885 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
POLB P06746 2/20 0.36
HPGD P15428 2/20 0.36
ADAM17 P78536 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 1/20 0.36
CTSK P43235 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6303397 0.81 HPGD (0.34) HPGD
SCHEMBL6302988 0.80 ALOX5 (0.34) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6297898 0.80 RAB9A (0.34) RAB9ASMN1; SMN2NPC1LMNACTSK
SCHEMBL6298317 0.78 ALDH1A1 (0.37) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL6303020 0.78 ALDH1A1 (0.40) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL6298287 0.78 LTB4R (0.31)
SCHEMBL6298492 0.78 LTB4R (0.31)
SCHEMBL6303501 0.78 CYP19A1 (0.38) RAB9ASMN1; SMN2NPC1ALDH1A1LMNA
SCHEMBL6296334 0.77 CYP3A4 (0.34) KMT2AALDH1A1PKMTSHRCTSK
SCHEMBL6363944 0.77 SMN1; SMN2 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US claimed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US claimed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP claimed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO claimed
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD RAB9A 3077/4885BRD4 653/4885MEN1 3684/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD RAB9A 3024/4885BRD4 623/4885MEN1 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.